Lynde, Charles

• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Alopecia
  Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Alopecia
  Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
  Details  PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Alopecia
  Baricitinib Treatment Increases Eyebrow and Eyelash ​Regrowth Up to ​52 Weeks
  Details  PDF
• SKIN The Journal of Cutaneous Medicine Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas - Rosacea
  Concurrent Administration of Ivermectin 1% Cream with Brimonidine 0.33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate-to-Severe Rosacea
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial
  Details  PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Posters from 2023 WCH Dermatology Conference: Psoriasis
  Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Atopic Dermatitis
  Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference) - Poster Presentations from FCPANP20 Clinical Conference®: Psoriasis
  Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference) - Poster Presentations from FCPANP20 Clinical Conference®: Psoriasis
  Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii - Urticaria
  Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii - Urticaria
  Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas - Urticaria
  Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas - Urticaria
  Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference) - Poster Presentations from FCPANP20 Clinical Conference®: Psoriasis
  Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas - Hidradenitis Suppurativa
  Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
  Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 8 No. 2 (2024): March 2024 Issue - Atopic Dermatitis
  Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis
  Abstract  PDF
• SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Miscellaneous
  A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis
  Abstract  Poster PDF